Table 2.

Patient demographics and disease characteristics (ITT population)

All patientsPart IPart II
Number of patients, n (%)N = 59N = 29N = 30
Age, years, n (%)
 Median60.859.262.3
 Range35–8235–7642–82
Race, n (%)
 Asian4 (7)2 (7)2 (7)
 Black/African American1 (2)01 (3)
 Caucasian51 (86)25 (86)26 (87)
 Other2 (3)1 (3)1 (3)
ECOG PS, n (%)
 016 (27)11 (38)5 (17)
 139 (66)16 (55)23 (77)
 24 (7)2 (7)2 (7)
Number of prior systemic regimens (per patient)
 Median3.63.43.8
 Range1–101–81–10
 Prior PARP inhibitora, n (%)1 (2)1 (3)0
 Prior angiogenesis inhibitorb, n (%)14 (23.7)8 (27.6)6 (20)
PFI (months)c
 Median4.05.24.2
 Mean (standard deviation)3.43 (2.21)3.4 (2.23)3.8 (2.22)
 Range0–7d1–70–6
Histology, n (%)
 Serous57 (97)28 (97)29 (97)
 Mixed epithelial2 (3)1 (3)1 (3)
 Endometrioid1 (2)1 (3)0
 Other/unknown1 (2)01 (3)
Grade
 I2 (3)1 (3)1 (3)
 II1 (2)1 (3)0
 III54 (92)26 (90)28 (93)
 Unknown2 (3)1 (3)1 (3)
  • aRucaparib.

  • bIn Part I: 3 received AMG386, 3 received cediranib, 1 received pazopanib, and 1 bevacizumab; In Part II: 6 received bevacizumab.

  • cPFI was derived as the time (months) between the date of last dose of the most recent prior platinum-based therapy and the date of first dose of carboplatin study treatment.

  • dOne patient had a PFI of 7 months.